Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Assets Average (2016 - 2025)

Historic Assets Average for Anika Therapeutics (ANIK) over the last 15 years, with Q3 2025 value amounting to $188.6 million.

  • Anika Therapeutics' Assets Average fell 2366.94% to $188.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $188.6 million, marking a year-over-year decrease of 2366.94%. This contributed to the annual value of $236.7 million for FY2024, which is 2362.01% down from last year.
  • As of Q3 2025, Anika Therapeutics' Assets Average stood at $188.6 million, which was down 2366.94% from $189.1 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Assets Average registered a high of $363.9 million during Q1 2021, and its lowest value of $188.6 million during Q3 2025.
  • In the last 5 years, Anika Therapeutics' Assets Average had a median value of $334.0 million in 2023 and averaged $300.1 million.
  • As far as peak fluctuations go, Anika Therapeutics' Assets Average decreased by 22.79% in 2023, and later plummeted by 2813.68% in 2025.
  • Quarter analysis of 5 years shows Anika Therapeutics' Assets Average stood at $350.2 million in 2021, then fell by 0.51% to $348.4 million in 2022, then fell by 14.07% to $299.4 million in 2023, then decreased by 27.5% to $217.1 million in 2024, then fell by 13.14% to $188.6 million in 2025.
  • Its Assets Average stands at $188.6 million for Q3 2025, versus $189.1 million for Q2 2025 and $196.7 million for Q1 2025.